PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31189930-0	2019	LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling.	enzalutamide	35-47	signal transducer and activator of transcription 3	Homo sapiens	127-132	
24307657-0	2014	Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells.	enzalutamide	51-63	signal transducer and activator of transcription 3	Homo sapiens	36-41	
24307657-3	2014	This study aimed to test whether overexpression of IL-6 and constitutive activation of Stat3 in prostate cancer cells increase resistance to enzalutamide.	enzalutamide	141-153	signal transducer and activator of transcription 3	Homo sapiens	87-92	
24307657-9	2014	Down regulation of Stat3 led to an increase in sensitivity of prostate cancer cells to enzalutamide.	enzalutamide	87-99	signal transducer and activator of transcription 3	Homo sapiens	19-24	
24307657-10	2014	Overexpression of constitutively active Stat3 in prostate cancer cells induced resistance to enzalutamide treatment.	enzalutamide	93-105	signal transducer and activator of transcription 3	Homo sapiens	40-45	
24307657-12	2014	The Stat3 inhibitor AG490 reversed enzalutamide resistance in prostate cancer cells, while combination treatment with enzalutamide and AG490 significantly inhibited cell growth and induced cell apoptosis.	enzalutamide	35-47	signal transducer and activator of transcription 3	Homo sapiens	4-9	
24307657-13	2014	CONCLUSIONS: This study demonstrates that the autocrine IL-6 pathway induces enzalutamide resistance in prostate cancer cells via the constitutive activation of Stat3.	enzalutamide	77-89	signal transducer and activator of transcription 3	Homo sapiens	161-166	
28031890-4	2015	STAT3 is also involved in the response to tyrosine kinase inhibitors sunitinib and axitinib, in patients with metastatic renal cell carcinoma, and to second-generation androgen receptor inhibitor enzalutamide in patients with advanced prostate cancer.	enzalutamide	196-208	signal transducer and activator of transcription 3	Homo sapiens	0-5	
28837141-0	2017	Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-beta1/STAT3 axis-regulated EMT.	enzalutamide	49-61	signal transducer and activator of transcription 3	Homo sapiens	85-90	
25970160-2	2015	Additionally, recent pre-clinical studies suggested enzalutamide might have the potential adverse effect of inducing metastasis of prostate cancer cells via Stat3 activation.	enzalutamide	52-64	signal transducer and activator of transcription 3	Homo sapiens	157-162	
25970160-10	2015	Knock down of Stat3 abrogated enzalutamide resistance resulting in reduced recruitment of AR to the PSA promoter in prostate cancer cells expressing IL6.	enzalutamide	30-42	signal transducer and activator of transcription 3	Homo sapiens	14-19	
25970160-11	2015	Moreover, niclosamide reversed enzalutamide resistance by down-regulating Stat3 target gene expression Stat3and abrogating recruitment of AR to PSA promoter resulting in PSA inhibition.	enzalutamide	31-43	signal transducer and activator of transcription 3	Homo sapiens	74-79	
25970160-12	2015	CONCLUSIONS: This study demonstrated the IL6-Stat3-AR axis in prostate cancer is one of the crucial mechanisms of enzalutamide resistance.	enzalutamide	114-126	signal transducer and activator of transcription 3	Homo sapiens	45-50